History

Since Aptahem was founded in 2014, the company has achieved several milestones on its way to develop a unique treatment for severe inflammatory conditions, such as sepsis.

2023

  • Finalized Phase 1a of the First in Human study with the lead candidate Apta-1 in sepsis

2022

  • Initiated a First In Human study with the drug candidate Apta-1 in sepsis
  • Patent approval for patent family 2 in Japan
  • Produced GMP certified Apta-1
  • Entered a new consortium with, among others, Örebro University
  • GLP toxicology studied showed very good tolerability in Apta-1

2021

  • Patent approval for patent family 1 in India
  • An important part of Apta-1’s mechanism of action identified
  • Patent approval for patent family 2 in Europe, USA and Turkey
  • Positive biological effects in a corona virus-induced lung damage model for treatment with Apta-1

2020

  • Entered collaboration with University Health Network in Canada

2019

  • Entered a consortium with Örebro University
  • The pharmaceutical formulation work was initiated in collaboration with Recipharm.
  • Published confirming results of Apta-1’s multi-mechanistic profile with potential within treatment of sepsis.

2018

  • Collaboration with the Seattle Children’s Research Institute was initiated.

2017

  • New development plan for Apta-1 in the indication for sepsis was presented.
  • Dr. Luiza Jedlina inventor to a new patent application filed to EPO (European Patent Office) based on new research results for Apta-1, patent family 2.

2016

  • Preclinical studies show that Apta-1 inhibits several inflammatory factors while simultaneously providing a strong stimulatory effect on certain parts of the body’s own anti-inflammatory response mechanisms and also effectively inhibits the occurrence of blood clots without an increase in bleeding.

2015

  • Aptahem was listed at Spotlight Stock Market (previously AktieTorget).
  • Patent approval in Europe, USA and Canada.
  • Preclinical studies show that Apta-1 has extended safe margins without noting any side effects, and that the candidate does not cause any bleeding at higher doses, unlike a market leading product.

2014

  • Aptahem was founded, based on the repurposed commercial therapeutic use proposition of the aptamers investigated and presented by Dr. Luiza Jedlina.

1996

  • Researchers Tina Persson and Johan Lindh discovered intriguing links between their areas of specialization which lead to the development of a new class of chemically derived biomolecules, known as aptamers. Consequently, the scientists developed aptamers against the malaria parasite that successfully disrupted rosetting. Rosetting is defined as the binding of two or more uninfected red blood cells (rbc) to a by malaria infected rbc and by binding more rbc’s this may lead to blockage of the blood vessels.